Integrin αVβ3 is a potential drug target because abnormal expression of v3 is linked to the development and progression of various diseases. Its role in
angiogenesis, in cancer and other diseases, is linked to the blood supply for problematic overgrowths. Inhibitors like
etaracizumab may be used as
antiangiogenics. One novel protein (ProAgio) has been designed to bind at an unusual site, and then induces
apoptosis by recruiting
caspase 8.
Fibronectin domain 10 contains the
RGD motif that αVβ3 recognizes. A high-affinity, pure
antagonist mutant has been discovered for this protein. == See also ==